Bioequivalence Study for Desloratadine OD Tablets 5 mg Under Fed Condition
Study Details
Study Description
Brief Summary
This is an open label, randomised, single dose, 2-way crossover, comparative bioequivalence study.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 1 |
Detailed Description
The objective of this study was to compare the rate and extent of absorption of Dr. Reddy's Laboratories Ltd., India, desloratadine ODT 5 mg and Schering Corporation, U.S.A.(Clarinex® 5 mg), desloratadine ODT 5 mg under fed conditions. The treatment phases were separated by a washout period of 14 days. 38 subjects were dosed and were enrolled in the study; 36 of these enrolled subjects completed the study.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Desloratadine OD tablets 5 mg Desloratadine OD tablets 5 mg of Dr. Reddy's Laboratories Limited |
Drug: Desloratadine
Desloratadine ODT 5 mg
Other Names:
|
Active Comparator: Clarinex Clarinex 5 mg of Schering Corporation Inc USA |
Drug: Desloratadine
Desloratadine ODT 5 mg
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Area under curve(AUC) [Pre-dose 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,8,12,24,36,48,72,96,120 and 144 hours post-dose]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Is the individual a healthy, normal adult man or woman who volunteers to participate?
-
Is s/he within 18 to 45 years of age, inclusive?
-
Is his/her BMI between 19 and 30 inclusive?
-
Is she willing to avoid pregnancy by abstaining from sexual intercourse with a non-sterile male partner, or by the use one of the following methods: diaphragm + spermicide or condom + spermicide (at least 14 days before dosing), intra-uterine contraceptive device or hormonal contraceptives (at least 4 week prior to dosing) or has she been surgically sterile or post-menopausal at least six months prior to entering into the study?
-
Is s/he considered reliable and capable of understanding his/her responsibility and role in the study?
-
Has s/he provided written informed consent?
Exclusion Criteria:
-
Does the individual have a history or allergy or hypersensitivity to desloratadine, milk or eggs?
-
Does s/he have clinically significant laboratory abnormalities that would interfere with the conduct or interpretation of the study or jeopardize his/her safety?
-
Does s/he have significant history or clinical evidence of auto-immune, cardiovascular, gastrointestinal, hematological, hematopoietic, hepatic, neurological, ongoing infection, pancreatic, or renal disease that would interfere with the conduct or interpretation of the study or jeopardize his/her safety?
-
Is she nursing?
-
Does s/he have serious psychological illness?
-
Does s/he have significant history (within the past year) or clinical evidence of alcohol or drug abuse?
-
Does s/he have a positive urine drug screen or a positive HIV-I, or hepatitis B or C screen, or a positive pregnancy test?
-
Is s/he unable to refrain from the use of alcohol or xanthine-containing foods or beverages during periods beginning 48 hours prior to study drug administration and ending when the last blood sample has been taken in each study period?
-
Has s/he used any prescription drug, other than hormonal contraceptives, during the 14 day period prior to study initiation, or any OTC drug during the 72 hour period preceding study initiation?
-
Is s/he unable to refrain from the use of all concomitant medications, other than hormonal contraceptives, during the study?
-
Has s/he donated or lost blood or participated in a clinical study which involved the withdrawal of a large volume of blood (480 mL or more), during the six week period preceding study initiation?
-
Has s/he donated plasma during the two week period preceding study initiation?
-
Has s/he received an investigational drug during the 30 day period preceding study initiated?
-
Has s/he used any tobacco products in the 3 months preceding drug administration?
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | SFBC Ft Myers Inc | Broadway | Florida | United States | 33901 |
Sponsors and Collaborators
- Dr. Reddy's Laboratories Limited
Investigators
- Principal Investigator: Antonio R Pizarro, MD, SFBC Anapharm
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 50633